Clinical Publications

Alzheimer's Research.

Accelerating the path to reversal through clinical genomics and system-level intervention planning. Validated by 10 accepted papers in 2026.

10 Accepted Alzheimer Papers 3 Oral Presentations 5 Major Venues Genomics & Foundation Models, 2026
Live Presentations

Presenting at AAAI-26 · Singapore

David Scott Lewis presenting our Alzheimer's AI research at the AAAI 2026 conference — Singapore Expo.

David Scott Lewis presenting Neuro-Symbolic AI for Alzheimer's Disease at AAAI-26 Singapore Expo
ORAL · AAAI-26 LMReasoning Workshop
"Neuro-Symbolic AI for Alzheimer's Disease" — Physics-Informed Biomarker Prediction & Verifiable Intervention Planning
David Scott Lewis presenting the Cell Reports Medicine foundational Alzheimer's reversal paper at AAAI-26
Cell Reports Medicine · January 2026
"Pharmacologic Reversal of Advanced Alzheimer's Disease in Mice" — the foundational paper powering our platform
Breakthrough Paper

The Foundational Discovery

The peer-reviewed breakthrough that inspired The Reversal Initiative — demonstrating the potential for pathology reversal in vivo.

Cell Reports Medicine · January 2026

"NAD+ Restoration and BBB Integrity Repair Reverses Advanced Alzheimer's in Mice"

Journal: Cell Reports Medicine  ·  Published: January 2026  ·  Model: 5xFAD (aggressive AD model)
Authors: Pieper Lab, Case Western Reserve / Harrington
DOI: 10.1016/j.xcrm.2025.102535
Note: AIXC provided computational support for this research, focusing on target identification and molecular docking validation.

Key Findings

Reversed amyloid plaque accumulation
Resolved tau neurofibrillary tangles
Repaired blood-brain barrier integrity
Restored cognitive function in vivo
Alzheimer's Clinical Genomics

2026 Alzheimer's Research — Full Portfolio

Ten peer-reviewed AI-methods papers on Alzheimer's disease, published across AAAI 2026, ICLR 2026 workshops, MLGenX, Gen², and AI4X 2026. Full inventory available on OpenReview.

AAAI 2026 · Bridge LMReasoning ORAL
Neuro-Symbolic AI for Alzheimer's Disease: Physics-Informed Biomarker Prediction and Verifiable Intervention Planning
David Scott Lewis, Enrique Zueco
Alzheimer'sBiomarker Prediction
ICLR 2026 · Workshop on World Models
Coherence-Validated Causal World Models for Multi-Scale Alzheimer's Disease Progression and Pharmacologic Reversal (C3WM)
David Scott Lewis, Enrique Zueco
Alzheimer'sReversal Trajectories
ICLR 2026 · Workshop on World Models
Reinforcement Learning with World Models for Optimizing Alzheimer's Disease Treatment Timing and Dosing
David Scott Lewis, Enrique Zueco
Alzheimer'sDosing Optimization
ICLR 2026 · Workshop LLM Reasoning
Neuro-Symbolic Active Causal Hypothesis Testing for NAD+-Centered Alzheimer's Disease Reversal (ACHT)
David Scott Lewis, Enrique Zueco
Alzheimer'sNAD+ Targets
ICLR 2026 · Workshop LLM Reasoning
Autoformalizing Biomedical Text into Verified Knowledge Graph Reasoning: A Neuro-Symbolic Architecture for Alzheimer's Disease
David Scott Lewis, Enrique Zueco
Alzheimer'sKnowledge Extraction
AI4X Accelerate 2026 · Singapore
Audited Causal Discovery Agents for Brain Resilience and Alzheimer's Reversal
David Scott Lewis, Enrique Zueco
Alzheimer'sBrain Resilience
MLGenX 2026 · ICLR
Agentic Active Causal Discovery for Alzheimer's Disease Reversal: Closing the Genomic Experimental Loop (AACD)
David Scott Lewis, Enrique Zueco
Alzheimer'sExperimental Design
MLGenX 2026 · Tiny Paper Track
Uncertainty-Aware Biomarker Discovery for Alzheimer's Disease Reversal: Bridging Mouse Models and Human Translation with Conformal Prediction (UABD)
David Scott Lewis, Enrique Zueco
Alzheimer'sTranslational Biomarkers
MLGenX 2026 · Tiny Paper Track
Active Learning for Optimal Experimental Design in Alzheimer's Disease Drug Discovery: Prioritizing NAD+-Enhancing Therapeutic Analogs via Multi-Objective Bayesian Optimization
David Scott Lewis, Enrique Zueco
Alzheimer'sDrug Discovery
Gen² 2026
Hierarchical Disease-State Generators for Neurodegenerative Genomics: A Benchmark Proposal for Intervention-Conditioned Multi-omic Generation
David Scott Lewis, Enrique Zueco
Alzheimer'sMulti-omics
Adjacent Biomedical Research

Broader Drug Discovery & Verified AI-for-Science Portfolio

Peer-reviewed work that surrounds the Alzheimer's focus — self-driving labs, virtual cells, drug-target discovery, and the verifier-first framework underlying the whole platform.

AI4X Accelerate 2026 · Singapore ORAL
ACHT-World: Causal World Models for Closed-Loop Self-Driving Laboratories
David Scott Lewis, Enrique Zueco
Self-Driving LabsCausal Models
AI4X Accelerate 2026 · Singapore ORAL
Latent World Models of Cell Painting Data for In Silico Phenotypic Screening
David Scott Lewis, Enrique Zueco, Junhan Wang
Cell PaintingPhenotypic Screening
Gen² 2026
Toward Generative Virtual Cells: Co-Evolving World Models and Perturbation Planners
David Scott Lewis, Enrique Zueco
Virtual CellsPerturbation Planning
AI4D3 2025
Active Causal Hypothesis Testing for AI-Guided Drug Target Discovery
David Scott Lewis, Enrique Zueco
Drug Target Discovery
ICLR 2026 · Workshop LLM Reasoning
Latent-Implicit Thinking with Proof-Carrying Neuro-Symbolic Outputs for Biomedical Discovery
David Scott Lewis, Enrique Zueco
Biomedical Discovery
ICML 2026 · AI4Science
Verifier-First Framework for AI Scientists
David Scott Lewis, Zhaoxiang Feng, Karl Wang, Junhan Wang, Saien Deng, Haley Yi
Verifier-First AIFoundational

Collaborate on Alzheimer's Research

Foundations, research labs, and hospitals — bring your scientific question, use our clinical genomics platform.

Partner With Us